

An Overview of Pharmacovigilance: A key for Drug Safety and Monitoring

Adesh B Wagh¹, Vaishnavi K Bochare², Ravina S Bodake³, Archana B Belhekar⁴, Gadge Shubham C⁵
Samarth Institute of Pharmacy Belhe, Maharashtra, India^{1,2,3,4,5}

Abstract: *Pharmacovigilance mentioned via way of means of the globe fitness organisation (WHO) because of the technological know-how and collection of sports the detection evaluation knowledge rejection of destructive effect or partner in nursing extraordinary drug linked trouble and a examine in human volunteers to reply particular fitness queries . an critical problem approximately the supply of banned tablets over the counter in india is that enough damaging drug reactions facts approximately those tablets have now no longer been reported .the maximum not unusual place classes of medications with drawn withinside the closing decade have been nonsteroidal Antiinflammatory tablets (28%), Antidiabetic (14.28%), Antiobesity (14.28%) , Antihistamines (14.28%), gastroprokinetics tablets (7.14%) breast most cancers and infertility tablets (7.14%). Today many pharmacovigilance facilities are running are running for drug protection tracking on this international pitch, however on the flip of the millenium pharmacovigilance faces foremost demanding situations in issue of heigher protection and tracking of drugs. In overview we can speak approximately drug protections, international pharmacovigilance facilities and their role, blessings and demanding situations of pharmacovigilance and its destiny attention in healthcares.*

Keywords: Pharmacovigilance, fitness, tablets, monitoring, drug.

REFERENCES

- [1]. World health organization. The importance of pharmacovigilance- safety monitoring of medicinal products. World health organization, Geneva.2002:
- [2]. Mann RD, Andrews EB, eds. John wiley & sons LTD, pharmacovigilance, chichester.2002.
- [3]. Shuka SS, Gidwani B, Pandey R , Rao SP, singh V Vyas A, importance pharmacovigilance in indian pharmaceutical industry, Asian journal of research in pharmaceutical science 2012 .
- [4]. Taofikat BA , savovi J, Ernst E, Method for causality assessment of adverse drug reactions a systemic review, drug safety, 2008;31(1):21-37.
- [5]. WHO, pharmacovigilance: ensuring the safe use of medicines, Geneva: WHO.2004;
- [6]. Loupi E Ponchon AC, Ventre JJ, Everux JC, Imputabilty of a teratogenic effect. Therapie, 1968;41(3):207-10
- [7]. Kulkarni SK, ghand book of experimental pharmacology, 3rd ed. Vallabh prakashan New Delhi, 2004; P21.
- [8]. Information about clinical trial. Available from: URL <http://www.temple.edu/pascope/about-trials.html>
- [9]. Clinical trial Wikipedia, the free encyclopedia: Available from, URL http://en.wikipedia.org/wiki/clinical_trial Jan 28 2008;
- [10]. Mashford ML, the Australian method of drug-event assessment: special workshop-regulatory. Drug Inf J 1984; 18(3-4):271-273.
- [11]. Vaccine safety. Vaccine safety advisory committee. Wkly epidemiol rec. 1999; 74:337-40. [PubMed] [Google Scholer]
- [12]. Ioannidis JP, lau J. Completeness of safety reporting in randomized trails: an evaluation of 7 medical areas. JAMA. 2001; 285: 437-43. [PubMed] [Google Scholer]
- [13]. Waller PC, wood SM, langman MJ, brecknridge AM, Rawlins MD. Review of company postmarketing surveillance studies. BMJ. 1992; 304: 1470-2. [PMC free article] [PubMed]
- [14]. Mackay FJ. Post-marketing studies: the work of the drug safety research unit. Drug saf. 1998; 19:343-53. [PubMed] [Google Scholer]